Kastle Therapeutics, LLC

Quick facts

Phase 2 pipeline

• ISIS 301012
  ISIS 301012 is an antisense oligonucleotide designed to bind to specific RNA sequences and modulate gene expression.

Phase 1 pipeline

• mipomersen sodium; warfarin sodium

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Kastle Therapeutics, LLC portfolio CI brief
• Kastle Therapeutics, LLC pipeline updates RSS

Related

• Sector hub: All tracked pharma companies